JPMorgan Chase & Co. Reiterates GBX 5,500 Price Target for AstraZeneca (AZN)

JPMorgan Chase & Co. set a GBX 5,500 ($77.12) price objective on AstraZeneca (LON:AZN) in a research note issued to investors on Thursday. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.

A number of other equities research analysts have also recently commented on the company. UBS Group set a GBX 4,550 ($63.80) price objective on AstraZeneca and gave the company a neutral rating in a research note on Tuesday, February 6th. Kepler Capital Markets raised their price objective on AstraZeneca from GBX 5,250 ($73.61) to GBX 5,300 ($74.31) and gave the company a buy rating in a research note on Tuesday, February 6th. Goldman Sachs Group set a GBX 3,800 ($53.28) price objective on AstraZeneca and gave the company a sell rating in a research note on Monday, February 5th. Credit Suisse Group reissued an outperform rating and issued a GBX 5,800 ($81.32) price objective on shares of AstraZeneca in a research note on Monday, February 5th. Finally, Barclays reissued a top pick rating and issued a GBX 6,300 ($88.33) price objective on shares of AstraZeneca in a research note on Monday, February 5th. Four analysts have rated the stock with a sell rating, seven have given a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company. AstraZeneca has a consensus rating of Hold and an average target price of GBX 5,211.65 ($73.07).

Shares of AstraZeneca (LON:AZN) opened at GBX 4,770 ($66.88) on Thursday. AstraZeneca has a one year low of GBX 4,260 ($59.73) and a one year high of GBX 5,520 ($77.40). The company has a market capitalization of $60,260.00 and a P/E ratio of 2,805.88.

In other news, insider Philip A. J. Broadley bought 415 shares of the firm’s stock in a transaction on Friday, February 2nd. The stock was acquired at an average cost of GBX 4,846 ($67.95) per share, with a total value of £20,110.90 ($28,198.12).

TRADEMARK VIOLATION NOTICE: This piece was posted by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of international trademark and copyright law. The correct version of this piece can be accessed at https://sportsperspectives.com/2018/02/11/jpmorgan-chase-co-reiterates-gbx-5500-price-target-for-astrazeneca-azn.html.

About AstraZeneca

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply